Long-term data from Phase III studies of upadacitinib in rheumatoid arthritis presented at conference
Long-term data from the SELECT-COMPARE, SELECT-MONOTHERAPY and SELECT-EARLY studies of the selective, reversible JAK inhibitor in patients with rheumatoid arthritis demonstrate sustained efficacy and a safety profile consistent with earlier reports.
Source:
Biospace Inc.